Stock Events

Stock Events

Aurinia Pharmaceuticals 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q4 2025
Next
0.17
0.54
0.92
1.3
Expected EPS
0.166296
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IKAP.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline develops treatments in areas similar to Aurinia, including autoimmune diseases, making them a direct competitor.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes in the immunology space, offering drugs that could be alternatives to Aurinia's products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad portfolio that includes treatments for autoimmune diseases, directly competing with Aurinia's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a strong presence in the immunology and oncology sectors, areas where Aurinia is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap187.56B
Amgen focuses on novel therapeutics in areas including inflammation, which overlaps with Aurinia's focus on autoimmune diseases.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the autoimmune disease market.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a range of treatments for autoimmune diseases, competing with Aurinia's lupus nephritis treatment.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences has a focus on inflammatory and respiratory diseases, making it a competitor in the autoimmune treatment market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca has a diverse portfolio that includes treatments for lupus, directly competing with Aurinia's lupus nephritis drug.
Roche
RHHBY
Mkt Cap321.08B
Roche, through its Genentech division, develops medications for autoimmune diseases, including lupus, making it a competitor.

About

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Show more...
CEO
Mr. Peter S. Greenleaf M.B.A.
Employees
300
Country
Canada
ISIN
CA05156V1022

Listings

STU
DE
IKAP.STU
MU
DE
IKAP.MU
LSE
GB
0UJF.LSE
F
DE
IKAP.F

0 Comments

Share your thoughts

FAQ

What is Aurinia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aurinia Pharmaceuticals stocks are traded under the ticker IKAP.MU.
When is the next Aurinia Pharmaceuticals earnings date?▼
Aurinia Pharmaceuticals is going to release the next earnings report on April 30, 2026.
What were Aurinia Pharmaceuticals earnings last quarter?▼
IKAP.MU earnings for the last quarter are 1.3 EUR per share, whereas the estimation was 0.18 EUR resulting in a +606.15% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Aurinia Pharmaceuticals have?▼
As of April 12, 2026, the company has 300 employees.
In which sector is Aurinia Pharmaceuticals located?▼
Aurinia Pharmaceuticals operates in the Other sector.
When did Aurinia Pharmaceuticals complete a stock split?▼
Aurinia Pharmaceuticals has not had any recent stock splits.
Where is Aurinia Pharmaceuticals headquartered?▼
Aurinia Pharmaceuticals is headquartered in Victoria, Canada.